Literature DB >> 22385240

Excessive CD4+ T cells co-expressing interleukin-17 and interferon-γ in patients with Behçet's disease.

J Shimizu1, K Takai, N Fujiwara, N Arimitsu, Y Ueda, S Wakisaka, H Yoshikawa, F Kaneko, T Suzuki, N Suzuki.   

Abstract

Excessive T helper type 1 (Th1) cell activity has been reported in Behçet's disease (BD). Recently, association of Th17 cells with certain autoimmune diseases was reported, and we thus investigated circulating Th17 cells in BD. CD4(+) CD45RO(-) (naive) T cells were cultured with Th0-, Th1-, Th2- and Th17-related cytokines and antibodies, and their mRNA was studied by real-time polymerase chain reaction (PCR). When naive CD4(+) T cells were cultured with Th1- and Th17-related cytokines, interferon (IFN)-γ mRNA and interleukin (IL)-17 mRNA were up-regulated, respectively, in BD patients. Naive CD4(+) T cells cultured in a Th17 cell-inducing condition expressed IL-23 receptor (IL-23R) mRNA excessively. IL-17 mRNA expression was induced only when naive CD4(+) T cells were cultured in the presence of IL-23. CD4(+) T cells cultured with Th17 cytokines expressed excessive RAR-related orphan receptor C (RORC) mRNA. Using intracellular cytokine staining, we found that CD45RO(+) (memory) CD4(+) T cells producing IL-17 and IFN-γ simultaneously were increased significantly. Memory CD4(+) T cells producing IFN-γ but not IL-17 decreased profoundly in BD patients. CD4(+) T cells producing IL-17 and IFN-γ simultaneously were found in BD skin lesions. Collectively, we found excessive CD4(+) T cells producing IL-17 and IFN-γ (Th1/Th17) cells in patients with BD, and possible involvement of IL-23/IL-23R pathway for the appearance of excessive Th1/Th17 cells.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22385240      PMCID: PMC3390496          DOI: 10.1111/j.1365-2249.2011.04543.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

Review 1.  Behçet's disease.

Authors:  T Sakane; M Takeno; N Suzuki; G Inaba
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

2.  Development, cytokine profile and function of human interleukin 17-producing helper T cells.

Authors:  Nicholas J Wilson; Katia Boniface; Jason R Chan; Brent S McKenzie; Wendy M Blumenschein; Jeanine D Mattson; Beth Basham; Kathleen Smith; Taiying Chen; Franck Morel; Jean-Claude Lecron; Robert A Kastelein; Daniel J Cua; Terrill K McClanahan; Edward P Bowman; Rene de Waal Malefyt
Journal:  Nat Immunol       Date:  2007-08-05       Impact factor: 25.606

3.  Excessive expression of Txk, a member of the Tec family of tyrosine kinases, contributes to excessive Th1 cytokine production by T lymphocytes in patients with Behcet's disease.

Authors:  H Nagafuchi; M Takeno; H Yoshikawa; M S Kurokawa; K Nara; E Takada; C Masuda; M Mizoguchi; N Suzuki
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

4.  Basic concepts of statistical analysis for surgical research.

Authors:  Laura D Cassidy
Journal:  J Surg Res       Date:  2005-09-02       Impact factor: 2.192

Review 5.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

6.  Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease.

Authors:  Guillaume Geri; Benjamin Terrier; Michelle Rosenzwajg; Bertrand Wechsler; Maxime Touzot; Danielle Seilhean; Tu-Anh Tran; Bahram Bodaghi; Lucile Musset; Vassili Soumelis; David Klatzmann; Patrice Cacoub; David Saadoun
Journal:  J Allergy Clin Immunol       Date:  2011-07-02       Impact factor: 10.793

7.  Increased expression of interleukin 17 in inflammatory bowel disease.

Authors:  S Fujino; A Andoh; S Bamba; A Ogawa; K Hata; Y Araki; T Bamba; Y Fujiyama
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

8.  Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease.

Authors:  Y Imamura; M S Kurokawa; H Yoshikawa; K Nara; E Takada; C Masuda; S Tsukikawa; S Ozaki; T Matsuda; N Suzuki
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

9.  Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers.

Authors:  Melike Melikoglu; Serpil Uysal; James G Krueger; Gilla Kaplan; Feride Gogus; Hasan Yazici; Stephen Oliver
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

10.  Phenotypic and functional features of human Th17 cells.

Authors:  Francesco Annunziato; Lorenzo Cosmi; Veronica Santarlasci; Laura Maggi; Francesco Liotta; Benedetta Mazzinghi; Eliana Parente; Lucia Filì; Simona Ferri; Francesca Frosali; Francesco Giudici; Paola Romagnani; Paola Parronchi; Francesco Tonelli; Enrico Maggi; Sergio Romagnani
Journal:  J Exp Med       Date:  2007-07-16       Impact factor: 14.307

View more
  35 in total

1.  Relative abundance of Megamonas hypermegale and Butyrivibrio species decreased in the intestine and its possible association with the T cell aberration by metabolite alteration in patients with Behcet's disease (210 characters).

Authors:  Jun Shimizu; Takao Kubota; Erika Takada; Kenji Takai; Naruyoshi Fujiwara; Nagisa Arimitsu; Yuji Ueda; Sueshige Wakisaka; Tomoko Suzuki; Noboru Suzuki
Journal:  Clin Rheumatol       Date:  2019-01-09       Impact factor: 2.980

Review 2.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

3.  Possible association of proinflammatory cytokines including IL1β and TNFα with enhanced Th17 cell differentiation in patients with Behcet's disease.

Authors:  Jun Shimizu; Kenji Takai; Erika Takada; Naruyoshi Fujiwara; Nagisa Arimitsu; Yuji Ueda; Sueshige Wakisaka; Tomoko Suzuki; Noboru Suzuki
Journal:  Clin Rheumatol       Date:  2015-05-14       Impact factor: 2.980

4.  [Update: Behçet's disease].

Authors:  I Kötter
Journal:  Z Rheumatol       Date:  2012-11       Impact factor: 1.372

Review 5.  Mucosal Lesions in an Allergy Practice.

Authors:  John J Kohorst; Alison J Bruce; Rochelle R Torgerson
Journal:  Curr Allergy Asthma Rep       Date:  2016-04       Impact factor: 4.806

Review 6.  Behçet syndrome: from pathogenesis to novel therapies.

Authors:  Gianluigi Mazzoccoli; Angela Matarangolo; Rosa Rubino; Michele Inglese; Angelo De Cata
Journal:  Clin Exp Med       Date:  2014-12-02       Impact factor: 3.984

7.  TH1 signatures are present in the lower airways of children with severe asthma, regardless of allergic status.

Authors:  Julia A Wisniewski; Lyndsey M Muehling; Jacob D Eccles; Brian J Capaldo; Rachana Agrawal; Debbie-Ann Shirley; James T Patrie; Lisa J Workman; Alexander J Schuyler; Monica G Lawrence; W Gerald Teague; Judith A Woodfolk
Journal:  J Allergy Clin Immunol       Date:  2017-09-20       Impact factor: 10.793

8.  Correlation between IL-17A/F, IL-23, IL-35 and IL-12/-23 (p40) levels in peripheral blood lymphocyte cultures and disease activity in Behcet's patients.

Authors:  Cemile Sonmez; Aysegul Atak Yucel; Turan Hilmi Yesil; Hamit Kucuk; Berna Sezgin; Ridvan Mercan; Ahmet Eftal Yucel; Gulderen Yanikkaya Demirel
Journal:  Clin Rheumatol       Date:  2018-03-20       Impact factor: 2.980

Review 9.  Is Behçet's disease a 'class 1-opathy'? The role of HLA-B*51 in the pathogenesis of Behçet's disease.

Authors:  M Giza; D Koftori; L Chen; P Bowness
Journal:  Clin Exp Immunol       Date:  2017-10-06       Impact factor: 4.330

10.  Influence of corticosteroid therapy on IL-18 and nitric oxide production during Behçet's disease.

Authors:  Fatmazohra Djaballah-Ider; Zineb Djeraba; Mourad Chemli; Nadjiba Dammene-Debbihe; Doulkifly Lounis; Houda Belguendouz; Yanis Medour; Samia Chaib; Chafia Touil-Boukoffa
Journal:  Inflammopharmacology       Date:  2018-03-29       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.